The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial
Open accessAbstract
Objectives To investigate the impact of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV. Design Two centre prospective double blind placebo controlled trial. Participants Children aged ≥8 weeks with HIV. Interventions Isoniazid or placebo given with co-trimoxazole either daily or three times a week. Setting Two tertiary healthcare centres in South Africa. Main outcome measures Mortality, incidence of tuberculosis, and adverse events. Results Data on 263 children (median age 24.7 months) were available when the data safety monitoring board recommended discontinuing the placebo arm; 132 (50%) were taking isoniazid. Median follow-up was 5.7 (interquartile range 2.0-9.7) months. Mortality was lower in the isoniazid group than in the placebo group (11 (8%) v 21 (16%), hazard ratio 0.46, 95% confidence interval 0.22 to 0.95, P=0.015) by intention to treat analysis. The benefit applied across Centers for Disease Control clinical categories and in all ages. The reduction in mortality was similar in children on three times a week or daily isoniazid. The incidence of tuberculosis was lower in the isoniazid group (5 cases, 3.8%) than in the placebo group (13 cases, 9.9%) (hazard ratio 0.28, 0.10 to 0.78, P=0.005). All cases of tuberculosis confirmed by culture were in children in the placebo group. Conclusions Prophylaxis with isoniazid has an early survival benefit and reduces incidence of tuberculosis in children with HIV. Prophylaxis may offer an effective public health intervention to reduce mortality in such children in settings with a high prevalence of tuberculosis. Trial registration. Clinical Trials NCT00330304
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Treatment of latent tuberculosis infection in HIV infected persons
Akolo, C., Adetifa, I., Shepperd, S., & Volmink, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000171.pub3 · Cited by 713
Accelerated course of human immunodeficiency virus infection after tuberculosis.
Whalen, C., Horsburgh, C. R., Hom, D., Lahart, C., Simberkoff, M., & Ellner, J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.1.7812542 · Cited by 535
Zar, H. J., Hanslo, D., Apolles, P., Swingler, G., & Hussey, G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17702-2 · Cited by 511
Self-citationNational Department of Health.
Whery, W. P. (1907) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1907.02520300070016 · Cited by 388
Chintu, C., Bhat, G., Walker, A., Mulenga, V, Sinyinza, F., Lishimpi, K., Farrelly, L., Kaganson, N., Zumla, A., Gillespie, S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17442-4 · Cited by 387
Chintu, C., Mudenda, V., Lucas, S., Nunn, A., Lishimpi, K., Maswahu, D., Kasolo, F., Mwaba, P., Bhat, G., Terunuma, H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11082-8 · Cited by 333
Bucher, H. C., Griffith, L. E., Guyatt, G. H., Sudre, P., Naef, M., Sendi, P., & Battegay, M. (1999) · Aids · doi:10.1097/00002030-199903110-00009 · Cited by 282
When to stop a clinical trial.
Pocock, S. J. (1992) · BMJ · doi:10.1136/bmj.305.6847.235 · Cited by 255 · cited 1×
“At the first meeting of the monitoring board, data up to 30 September 2003 were analysed. Of the 129 children enrolled 13/61 died in the placebo group and 4/68 died in the isoniazid group (P=0.009). The second meeting of the board in April 2004 considered data up to 30 December 2003. At that time, of the 148 children…”
BackgroundInfluentialMadhi, S. A., Petersen, K., Madhi, A., Khoosal, M., & Klugman, K. P. (2000) · Clinical Infectious Diseases · doi:10.1086/313925 · Cited by 254
Cited by
Perez-Velez, C. M., & Marais, B. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1008049 · Cited by 572
Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Crane, C. M., Burgos, M., et al. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6901a1 · Cited by 495
Newton, S. M., Brent, A. J., Anderson, S., Whittaker, E., & Kampmann, B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70182-8 · Cited by 480
Pediatric Tuberculosis: Global Overview and Challenges
Swaminathan, S., & Rekha, B. (2010) · Clinical Infectious Diseases · doi:10.1086/651490 · Cited by 377
Martinez, L., Cords, O., Horsburgh, C. R., Andrews, J. R., Acuna-Villaorduna, C., Desai Ahuja, S., Altet, N., Augusto, O., Baliashvili, D., Basu, S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30166-5 · Cited by 349
Self-citation
Metadata
- Authors
- Zar, H. J., Cotton, M. F., Strauss, S., Karpakis, J., Hussey, G., Schaaf, H. S., Rabie, H., & Lombard, C. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2006-11-03
- Volume
- 334
- Issue
- 7585
- Pages
- 136
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2155753953
- Cited by
- 254
- References
- 27
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. https://app.cochat.ai/papers/10.1136/bmj.39000.486400.55
- The paper
- Zar, H. J., Cotton, M. F., Strauss, S., Karpakis, J., Hussey, G., Schaaf, H. S., Rabie, H., & Lombard, C. J. (2007). Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. https://doi.org/10.1136/bmj.39000.486400.55
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.